文献速递痛风与晶体性关节病

美国65岁及以上成年人接种重组带状疱疹疫苗后新发痛风的风险

Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥65 years.
PubMed 文献 · Semin Arthritis Rheum · 2024-07-15

该病例-自身对照风险区间研究纳入美国65岁及以上按服务付费的联邦医疗保险受益人,暴露为2018年或2019年接种至少一剂两剂次重组带状疱疹疫苗(RZV),风险窗为接种后第1-30天、对照窗为第31-60天,采用条件泊松回归估计新发痛风的相对风险(RR)。1290例接种RZV后新发痛风者的RR为1.00(95%CI 0.90, 1.12),符合剂量要求的敏感性分析(n=959)RR为0.99(95%CI 0.87, 1.13),剂量特异性、季节性调整及COVID-19调整分析结果不变;作者认为RZV与65岁及以上联邦医疗保险人群新发痛风风险增加无显著关联。

要点

  • 接种RZV后第1-30天新发痛风风险与第31-60天相比无显著差异,RR 1.00(95%CI 0.90, 1.12)。
  • 符合剂量要求的敏感性分析(n=959)RR为0.99(95%CI 0.87, 1.13),结果一致。
  • 作者认为RZV与65岁及以上联邦医疗保险人群新发痛风风险增加无显著关联。

核心结论

  • 作者认为,在65岁及以上联邦医疗保险人群中,接种RZV与新发痛风风险增加无显著关联。

研究设计与样本

  • 病例-自身对照风险区间研究,纳入美国65岁及以上按服务付费的联邦医疗保险(Part A、B、D)受益人队列。
  • 暴露为2018年或2019年接种至少一剂两剂次RZV方案;风险窗为接种后第1-30天,对照窗为第31-60天。
  • 新发痛风定义为风险窗或对照窗内首次痛风发作,且此前365天内无痛风证据;采用条件泊松回归估计RR及95%CI。
  • 敏感性分析包括:在首剂后60-183天接种第二剂者的符合剂量要求亚组分析、剂量特异性分析、季节性调整、针对疫情检测偏倚的COVID-19调整。

主要发现

  • 1290例接种RZV后新发痛风者以白人(86.98%)、男性(61.16%)、70-79岁(55.82%)为主。
  • 风险窗相对对照窗的新发痛风RR为1.00(95%CI 0.90, 1.12)。
  • 符合剂量要求的敏感性分析(n=959例新发痛风)RR为0.99(95%CI 0.87, 1.13)。
  • 剂量特异性、季节性调整及COVID-19敏感性分析结果均不变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Assess the risk of incident gout following exposure to recombinant zoster vaccine (RZV). METHODS: This case-only, self-controlled risk interval study included a cohort of US fee-for-service Medicare (Part A, B, and D) beneficiaries aged ≥65 years. The exposure was receipt of at least one dose of the two-dose RZV regimen in 2018 or 2019. The risk and control windows were days 1-30 and days 31-60, respectively, following vaccination. Incident gout was defined as the first episode of gout during the risk or control window, with no evidence of gout in the last 365 days. We estimated the relative risk (RR) and 95 % confidence interval (CI) of incident gout in the risk window relative to the control window, using conditional Poisson regression models. Sensitivity analyses included a dose-compliant subanalysis of individuals who received dose 2 60-183 days after dose 1; dose-specific analysis; seasonality adjustment; and COVID-19 adjustment for potential detection bias due to the pandemic. RESULTS: The 1290 RZV-exposed individuals with incident gout were primarily White (86.98 %), male (61.16 %), and aged 70-79 years (55.82 %). The RR of incident gout was 1.00 (95 % CI 0.90, 1.12). In the dose-compliant sensitivity analysis (n = 959 cases of incident gout), the RR of incident gout was 0.99 (95 % CI 0.87, 1.13). The findings were unchanged in the dose-specific, seasonality, and COVID-19 sensitivity analyses. CONCLUSION: The findings suggest that RZV is not significantly associated with an increased risk of incident gout in the Medicare population aged ≥65 years.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Zhang C, Amill-Rosario A, Johnson A, et al. Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥65 years. Semin Arthritis Rheum. 2024. PMID: 39047625. doi:10.1016/j.semarthrit.2024.152515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。